Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
News
Research News
Conference News
Plain English
Forums
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
Interviews
Resources
What We Know
SchizophreniaGene
Animal Models
Drugs in Trials
Research Tools
Grants
Jobs
Conferences
Journals
Community Calendar
General Information
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
History
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Animal Models

Important Notice: The Forum does not endorse any medical product or therapy. ALL medications and supplements should be taken ONLY under the supervision of a physician, due to the possibility of side-effects, drug interactions, etc.

Animal Model: NMDA Receptor Antagonist Rx (MK801, PCP, Ketamine)-Acute, Rodent
Preparation Type: Drug-Induced Preparations
DA-related behavior: Increases locomotor activity and stereotopy, ataxia
Gating: Disrupted PPI 1 day after PCP, and 15 minutes after PCP, but not 7 or 28 days later, abnormal latent inhibition
Cognitive behavior: Decreased working memory, disrupted fear conditioning, long-term spatial memory deficits, impaired passive-avoidance, recognition memory deficit
Social behavior: Impaired social interaction
Molecular/morphological signature: Impaired LTP, decreased AMPA receptor density
Response to APD: Enhanced locomotor responses blocked by APD, glycine transporter-1 inhibition rescues LTP, PPI disruption attenuated by admatine, glycine, D-serine, not D-cycloserine, fear conditioning disruption prevented by clozapine, but not haloperidol, LI abnormalities reversed by risperidone and M100907, passive avoidance impairment reversed by lurasidone, recognition memory deficit reversed by clozapine and D-serine, but not haloperidol
Citations: Jentsch JD, Roth RH. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 1999 Mar 1; 20(3):201-25. Abstract

Manahan-Vaughan, D., D. von Haebler, C. Winter, G. Juckel, and U. Heinemann, A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus, 2008. 18(2): p. 125-34. Abstract

Manahan-Vaughan, D., V. Wildforster, and C. Thomsen, Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1). Eur J Neurosci, 2008. 28(7): p. 1342-50. Abstract

Gaisler-Salomon, I., L. Diamant, C. Rubin, and I. Weiner, Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. Psychopharmacology (Berl), 2008. 196(2): p. 255-67. Abstract

Kanahara, N., E. Shimizu, S. Ohgake, Y. Fujita, M. Kohno, T. Hashimoto, D. Matsuzawa, Y. Shirayama, K. Hashimoto, and M. Iyo, Glycine and D: -serine, but not D: -cycloserine, attenuate prepulse inhibition deficits induced by NMDA receptor antagonist MK-801. Psychopharmacology (Berl), 2008. 198(3): p. 363-74. Abstract

Karasawa, J., K. Hashimoto, and S. Chaki, D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res, 2008. 186(1): p. 78-83. Abstract

Ishiyama, T., K. Tokuda, T. Ishibashi, A. Ito, S. Toma, and Y. Ohno, Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol, 2007. 572(2-3): p. 160-70. Abstract

Palsson, E., K. Fejgin, C. Wass, and D. Klamer, Agmatine attenuates the disruptive effects of phencyclidine on prepulse inhibition. Eur J Pharmacol, 2008. 590(1-3): p. 212-6. Abstract

Pietersen, C.Y., F.J. Bosker, J. Doorduin, M.E. Jongsma, F. Postema, J.V. Haas, M.P. Johnson, T. Koch, T. Vladusich, and J.A. den Boer, An animal model of emotional blunting in schizophrenia. PLoS ONE, 2007. 2(12): p. e1360. Abstract

Zavitsanou, K., V. Nguyen, K. Newell, P. Ballantyne, and X.F. Huang, Rapid cortico-limbic alterations in AMPA receptor densities after administration of PCP: implications for schizophrenia. J Chem Neuroanat, 2008. 36(2): p. 71-6. Abstract


December 18, 2014
SRF News
SRF Comments
Text Size
Reset Text Size
Share/Bookmark

See our latest webinar, Cognition and Treatment Resistance in Schizophrenia, held November 10, 2014.

See our last webinar, Research Domain Criteria (RDoC) Applied to Verbal Hallucinations, held May 28, 2014.
Copyright © 2005- 2014 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright